Home › All Companies › CAI

Caris Life Sciences, Inc. (CAI)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-08

Key Insights

  • The filing reveals Caris Life Sciences operates two primary business segments: Molecular Profiling Services and Pharma Research and Development Services, with customer concentration risk evident from identified major commercial payers requiring revenue diversification monitoring.
  • The company maintains a 2023 Term Loan facility with secured debt arrangements, indicating reliance on external financing for operations and potential covenant considerations that could impact financial flexibility.
  • Significant share-based compensation activity is evident through multiple equity plans (2020 and 2025 Incentive Plans) with RSUs, performance shares, and employee stock options outstanding, which could create notable dilution to existing shareholders.
  • The filing demonstrates ongoing investment in infrastructure with capitalized assets including laboratory equipment, software development, and leasehold improvements, reflecting growth investments in core molecular profiling and R&D capabilities.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-05-07

Key Insights

  • Caris Life Sciences announced Q1 2026 financial results on May 7, 2026, indicating the company is maintaining its regular earnings reporting cadence and SEC compliance as a Nasdaq-listed public company.
  • The filing is a routine 8-K for earnings announcement with the actual financial details contained in the press release (Exhibit 99.1), which is not provided in this document, limiting detailed analysis of operational performance.
  • The company maintains emerging growth company status, which provides regulatory flexibility for compliance timelines, though it has not elected to use extended transition periods for new accounting standards.
  • Senior Vice President and CFO Luke Power signed the filing, confirming continued stability in the company's financial leadership and oversight.
Sentiment: Neutral Significance: 2/10
View Original Filing →
Current Report Filed: 2026-04-02

Key Insights

  • Caris Life Sciences has secured a significant new credit facility, including a $400 million initial term loan, a $300 million delayed draw term loan, and a $500 million incremental facility. This additional financing provides the company with substantial resources to pursue strategic acquisitions and growth initiatives.
  • The new credit agreement replaces the company's previous credit facility, suggesting improved financing terms and conditions that may benefit the company's financial flexibility and cost of capital.
  • The credit agreement includes customary covenants and restrictions, which investors should monitor to ensure the company maintains compliance and financial discipline as it executes on its growth plans.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • David D. Halbert, the founder, chairman, and CEO of Caris Life Sciences, has acquired a substantial direct and indirect ownership stake in the company, holding over 123.6 million shares or around 10% of the total outstanding shares.
  • Halbert's ownership is spread across multiple entities, including Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd, Caris Investment III Ltd, and Halbert Family Capital, LLC, indicating a complex ownership structure.
  • The award of 320,112 restricted stock units to Halbert further increases his alignment with shareholders, as the vesting of these units will be dependent on the company's performance.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • Brian J. Brille, the Vice Chairman and Executive Vice President of Caris Life Sciences, Inc. (CAI), acquired 83,162 shares of the company's common stock through a restricted stock unit award.
  • Brille also holds an indirect beneficial ownership of 500,000 shares of CAI common stock through a family trust, indicating his significant stake in the company.
  • The Form 4 filing suggests that Brille continues to have a strong commitment to and confidence in the company's long-term growth and performance.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • The reporting person, David Baxley Spetzler, who is the President of Caris Life Sciences, Inc. (CAI), acquired 83,162 shares of common stock through a restricted stock unit award.
  • The acquisition of 83,162 shares increases Spetzler's direct beneficial ownership of CAI common stock to 543,939 shares, indicating a significant insider investment in the company.
  • The timing of the transaction, in March 2026, suggests Spetzler's confidence in the company's future performance and aligns his interests with those of other shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • The reporting person, John Russel Denton, acquired 63,971 shares of Caris Life Sciences, Inc. common stock through a restricted stock unit award, indicating potential confidence in the company's future.
  • Denton also holds an indirect beneficial ownership of 9,184 shares of common stock through a trust, further demonstrating his investment in the company.
  • The transaction was made on March 6, 2026, suggesting recent insider activity and ongoing commitment to the company.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • The reporting person, Luke Thomas Power, acquired 63,971 shares of Caris Life Sciences, Inc. (CAI) common stock through a restricted stock unit award, increasing his direct beneficial ownership to 163,542 shares.
  • This transaction reflects the company's executive compensation program, as Power holds the role of Senior Vice President, Chief Financial Officer, and Chief Accounting Officer.
  • The filing does not indicate any sales or disposals of Caris Life Sciences shares by the reporting person, suggesting potential confidence in the company's long-term prospects.
Sentiment: Positive Significance: 5/10
View Original Filing →
Annual Report Filed: 2026-03-03

Key Insights

  • Caris Life Sciences, Inc. (CAI) reported a significant increase in revenue and gross profit in fiscal year 2025 compared to prior years, indicating strong growth in its core molecular profiling and pharma research and development services.
  • The company has made notable investments in property, plant, and equipment, as well as in non-current assets, suggesting ongoing expansion and innovation efforts.
  • Caris Life Sciences has a mix of current and non-current liabilities, including accrued liabilities, long-term debt, and other non-current liabilities, which will require close monitoring of the company's capital structure and liquidity position.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-03-02

Key Insights

  • Insider Lloyd Minor, a director of Caris Life Sciences, acquired 2,492 shares of the company's common stock at a price of $20.06 per share, increasing his direct ownership to 18,621 shares.
  • The shares were acquired in lieu of cash compensation for Minor's 2025 board retainer fees, indicating a willingness to receive equity as part of his director compensation.
  • This transaction suggests Minor's confidence in the company's long-term prospects and aligns his interests with those of other shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-02-26

Key Insights

  • Caris Life Sciences reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's operations and financial performance.
  • The company announced progress on its Caris Detect multi-cancer early detection test, with the completion of the interim readout of the Achieve 1 study supporting the upcoming launch of the product.
  • Investors will likely be interested in the financial details and the company's outlook for the Caris Detect test, which could be a significant growth driver for Caris Life Sciences.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-13

Key Insights

  • Insider Peter M. Castleman acquired 2,500 additional shares of Caris Life Sciences, Inc. (CAI) through the exercise of stock options, indicating his continued confidence in the company.
  • Castleman also holds a significant indirect beneficial ownership of 10,270,906 shares through CLS-PF-SPE, LLC, suggesting he has a substantial stake in the company.
  • The stock option exercise and Castleman's large indirect ownership position suggest he believes in the long-term growth potential of Caris Life Sciences.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • Caris Life Sciences reported preliminary unaudited Q4 2025 and full-year 2025 financial results, indicating the company's continued growth and performance.
  • The company will be presenting at the 2026 J.P. Morgan Healthcare Conference, providing an opportunity for investors to get updated on the company's strategic initiatives.
  • As an emerging growth company, Caris Life Sciences has elected to take advantage of the extended transition period for complying with new or revised financial accounting standards.
Sentiment: Positive Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.